Divi's Lab share: Q2 profit up 64%, market value crosses Rs 3 lakh crore

Shares of Divi's Laboratories rose about 6% in early trade on Monday, 9 November 2026, extending their rally after the drug ingredient maker reported a 64% jump in consolidated net profit for the July-September quarter (Q2 FY27). Net profit rose to Rs 1,127 crore from Rs 689 crore a year earlier, and revenue from operations grew 35.4% to Rs 3,676 crore. Market reports said the rally took the company's market value past Rs 3 lakh crore (Rs 3 trillion), with the stock up about 15% over two sessions after the results.

Divi's Laboratories makes active pharmaceutical ingredients (APIs), the chemical compounds that give a medicine its effect, and sells them to drug makers around the world. It earns money in two ways: generic APIs, which many companies can make and which face price competition, and custom synthesis, where it produces complex ingredients under contract for big pharmaceutical companies, often for patented drugs. The Q2 numbers show that the second business is now carrying the company.

Brokerage analysts credited the improvement to backward integration at the company's Unit 3, meaning it now makes more of its own raw materials, and to its growing capability in peptides, the chain-like molecules used in a new class of drugs. Making its own inputs lowers costs, which helps explain why profit rose almost twice as fast as revenue.

The share move matters for India's pharma sector. Crossing a Rs 3 lakh crore market value is a milestone for the company. For the market, the results are a sign that India's contract manufacturing for global drug makers is growing quickly even as plain generics face falling prices.

Peepals calculation: The 42.6% EBITDA margin on Rs 3,676 crore of revenue works out to about Rs 1,566 crore of EBITDA (3,676 × 0.426). Net profit equals about 30.7% of revenue (1,127 ÷ 3,676). Custom synthesis, at about Rs 2,200 crore, made up roughly 60% of the quarter's revenue (2,200 ÷ 3,676). A year earlier, revenue was about Rs 2,715 crore (3,676 ÷ 1.354), so the company added about Rs 961 crore of quarterly sales in a year. Our calculation from the reported figures.

Short-term: The results have pushed the stock sharply higher in the sessions since they were released, and brokerages have raised their targets. Moves this large can reverse, and analysts' targets are their own views, not forecasts of what will happen.

Long-term: The company's growth now rests on custom synthesis and peptide work for global drug makers. Whether management's double-digit growth guidance for the second half holds will decide whether the higher valuation is sustained. Pressure on generic API prices remains a drag.

Who is affected: Shareholders of Divi's Laboratories, including mutual funds that hold pharma stocks; its employees; and global pharmaceutical companies that rely on it for ingredients.

What to watch next: Whether the company delivers the double-digit revenue growth it has guided for the second half of FY27, which will show up in its October-December and January-March quarterly results.

Questions and Answers